Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sanofi launches...

    Sanofi launches Combiflam Icyhot pain relief topical in India

    Written by Ruby Khatun Khatun Published On 2017-09-12T12:35:31+05:30  |  Updated On 18 Aug 2021 3:00 PM IST

    Mumbai: Sanofi India on Monday said it has expanded its consumer healthcare portfolio by launching Combiflam Icyhot, a topical analgesic in the pain-care segment.


    "We have launched Combiflam Icyhot, an over-the-counter product, which will be available in two formats - gel and spray, for instant and long-lasting relief to people suffering from muscle pains and sprains," Sanofi general manager - consumer healthcare, India & South Asia Nikhilesh Kalra told here.


    Sanofi India's Consumer Healthcare Business Unit has a strong presence in four segments, namely pain-care, digestive health, allergy solutions, and vitamins, minerals, and supplements.


    Typically, people choose the format of their painkiller depending on the type of pain they are suffering from, said Kalra.


    When it comes to seeking relief from muscular pains including neck, shoulder and back pain, topicals are the most preferred format. To address this gap in our pain segment, we have brought the Icyhot brand from Sanofi USA, and are manufacturing it indigenously to offer our Indian consumers a high quality over-the- counter product, at affordable prices, Kalra said.


    "Combiflam is one of our flagship prescription brands and is present in 1 of 3 Indian households for over 30 years. Building on this legacy, the launch of Combiflam Icyhot gel and spray in the over-the- counter segment further expands our consumer healthcare portfolio," Sanofi managing director-India and vice president - South Asia Shailesh Ayyangar said.


    The company sees a big opportunity in the pain-care segment as country's pain relief market is estimated at Rs 4,700 crore, of which topicals is estimated at Rs 2,800 crore, Kalra said.


    Going forward, the company hopes to launch more OTC products in allergy solutions, pain-care, and digestive health segments, Kalra added.

    CombiflamCombiflam Icyhotconsumer healthcareIndialaunchesmuscle painsNikhilesh Kalrapain reliefSanofiSanofi IndiaShailesh Ayyangarsprainstopical analgesic
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok